The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 35, No. 7, pp. 935-942. DOI 10.1345/aph.10220
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pegram, A.
Right arrow Articles by Kennedy, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pegram, A.
Right arrow Articles by Kennedy, L.

Research Articles

Prevention and treatment of veno-occlusive disease

AA Pegram and LD Kennedy

OBJECTIVE: To review the current options for prevention and treatment of veno-occlusive disease in bone marrow transplant patients. DATA SOURCES: Articles were selected from a MEDLINE search (1966-October 1999) using the key terms veno-occlusive disease and bone marrow transplantation. In addition, references of all articles were examined for articles not found in the computer-based search. DATA EXTRACTION: All clinical trials, case-control studies, and case reports were evaluated. RESULTS: Heparin, low-molecular-weight heparin, prostaglandin E1, ursodiol, and glutamine have been studied for prevention of veno-occlusive disease. Heparin has been studied most extensively; however, no preventive regimen has a defined role in therapy. For treatment, tissue plasminogen activator has been evaluated most thoroughly, yet its safety and efficacy have not been clearly established in patients with veno-occlusive disease. Other possible treatment options include antithrombin-III, defibrotide, glutamine plus vitamin E, and surgery. CONCLUSIONS: Based on the available data, the most promising agents are ursodiol for prevention and defibrotide or glutamineplus vitamin E for treatment of veno-occlusive disease. Further clinical trials are needed to establish the appropriate preventive and treatment options available for bone marrow transplant patients suffering from veno-occlusive disease. To date, such decisions depend largely on poorly designed trials, case reports, and clinical experience.


This article has been cited by other articles:


Home page
 BloodHome page
L. Benimetskaya, S. Wu, A. M. Voskresenskiy, C. Echart, J.-F. Zhou, J. Shin, M. Iacobelli, P. Richardson, K. Ayyanar, and C. A. Stein
Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease
Blood, November 15, 2008; 112(10): 4343 - 4352.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. B Ibrahim, E. Peres, R. Dansey, M. H Abidi, E. M Abella, and J. Klein
Anti-Thrombin III in the Management of Hematopoietic Stem-Cell Transplantation-Associated Toxicity
Ann. Pharmacother., June 1, 2004; 38(6): 1053 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Eissner, G. Multhoff, A. Gerbitz, S. Kirchner, S. Bauer, S. Haffner, D. Sondermann, R. Andreesen, and E. Holler
Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide
Blood, June 17, 2002; 100(1): 334 - 340.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.